Biotech Company Settles Claims of Fraudulent Genetic Test Orders

A New Jersey biotechnology company agreed to pay $5.4 million to resolve allegations that it violated the Anti-Kickback Statue of the False Claims Act, the Justice Department announced Wednesday.

Admera Health made commission-based payments to independent contractor marketers in return for recommending or arranging for the ordering of genetic testing services in violation of the AKS, the department said. The AKS prohibits offering or paying remuneration in return for arranging for or recommending items or services covered by Medicare and other federally funded programs.

In addition to paying the civil settlement, Admera will pay an additional $147,851 to individual ...